La combinación de quimioterapia intravenosa e intraperitoneal mejora la supervivencia en el cáncer de ovario

Translated title of the contribution: The combination of intravenous and intraperitoneal chemotherapy improves survival for women ovarian cancer

Lucas Minig, Edward Trimble

Research output: Contribution to journalReview article

Abstract

There is compelling evidence from seven RCTs that a combination of intravenous (IV) and intraperitoneal (IP) chemotherapy given after optimal cytoreductive surgery significantly improves survival for women with FIGO stage III epithelial ovarian cancer. On the basis of this data, the US-NCI issued a Clinical Announcement in January 2006 recommending that women and their physicians consider such combined IV/IP chemotherapy where appropriate. Despite ongoing educational efforts, IP/IV regimens have not become the standard of care in many hospitals. Ongoing clinical research seeks to reduce the toxicity associated with IP chemotherapy while retaining efficacy and integrating new biological approaches to treatment. Copyrigth

Original languageSpanish
Pages (from-to)323-325
Number of pages3
JournalSalud(i)Ciencia
Volume18
Issue number4
StatePublished - Jun 2011
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Drug Therapy
Survival
Women Physicians
National Cancer Institute (U.S.)
Standard of Care
Research
Therapeutics
Ovarian epithelial cancer

Keywords

  • Chemotherapy
  • Epithelial ovarian cancer
  • Intraperitoneal chemotherapy
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

La combinación de quimioterapia intravenosa e intraperitoneal mejora la supervivencia en el cáncer de ovario. / Minig, Lucas; Trimble, Edward.

In: Salud(i)Ciencia, Vol. 18, No. 4, 06.2011, p. 323-325.

Research output: Contribution to journalReview article

@article{ff3fcf8477814f0a87c90d8453d748ad,
title = "La combinaci{\'o}n de quimioterapia intravenosa e intraperitoneal mejora la supervivencia en el c{\'a}ncer de ovario",
abstract = "There is compelling evidence from seven RCTs that a combination of intravenous (IV) and intraperitoneal (IP) chemotherapy given after optimal cytoreductive surgery significantly improves survival for women with FIGO stage III epithelial ovarian cancer. On the basis of this data, the US-NCI issued a Clinical Announcement in January 2006 recommending that women and their physicians consider such combined IV/IP chemotherapy where appropriate. Despite ongoing educational efforts, IP/IV regimens have not become the standard of care in many hospitals. Ongoing clinical research seeks to reduce the toxicity associated with IP chemotherapy while retaining efficacy and integrating new biological approaches to treatment. Copyrigth",
keywords = "Chemotherapy, Epithelial ovarian cancer, Intraperitoneal chemotherapy, Treatment",
author = "Lucas Minig and Edward Trimble",
year = "2011",
month = "6",
language = "Spanish",
volume = "18",
pages = "323--325",
journal = "Salud (i) Ciencia",
issn = "1667-8982",
publisher = "Sociedad Iberoamericana de Informacion Cientifica",
number = "4",

}

TY - JOUR

T1 - La combinación de quimioterapia intravenosa e intraperitoneal mejora la supervivencia en el cáncer de ovario

AU - Minig, Lucas

AU - Trimble, Edward

PY - 2011/6

Y1 - 2011/6

N2 - There is compelling evidence from seven RCTs that a combination of intravenous (IV) and intraperitoneal (IP) chemotherapy given after optimal cytoreductive surgery significantly improves survival for women with FIGO stage III epithelial ovarian cancer. On the basis of this data, the US-NCI issued a Clinical Announcement in January 2006 recommending that women and their physicians consider such combined IV/IP chemotherapy where appropriate. Despite ongoing educational efforts, IP/IV regimens have not become the standard of care in many hospitals. Ongoing clinical research seeks to reduce the toxicity associated with IP chemotherapy while retaining efficacy and integrating new biological approaches to treatment. Copyrigth

AB - There is compelling evidence from seven RCTs that a combination of intravenous (IV) and intraperitoneal (IP) chemotherapy given after optimal cytoreductive surgery significantly improves survival for women with FIGO stage III epithelial ovarian cancer. On the basis of this data, the US-NCI issued a Clinical Announcement in January 2006 recommending that women and their physicians consider such combined IV/IP chemotherapy where appropriate. Despite ongoing educational efforts, IP/IV regimens have not become the standard of care in many hospitals. Ongoing clinical research seeks to reduce the toxicity associated with IP chemotherapy while retaining efficacy and integrating new biological approaches to treatment. Copyrigth

KW - Chemotherapy

KW - Epithelial ovarian cancer

KW - Intraperitoneal chemotherapy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84863832329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863832329&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:84863832329

VL - 18

SP - 323

EP - 325

JO - Salud (i) Ciencia

JF - Salud (i) Ciencia

SN - 1667-8982

IS - 4

ER -